Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Breast Cancer Research and Treatment
Erschienen in: Breast Cancer Research and Treatment 3/2011

01.06.2011 | Brief Report

BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer

verfasst von: Michelle W. Wong, Cecilia Nordfors, David Mossman, Gordana Pecenpetelovska, Kelly A. Avery-Kiejda, Bente Talseth-Palmer, Nikola A. Bowden, Rodney J. Scott

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

Mutations in the recognized breast cancer susceptibility genes BRCA1, BRCA2, TP53, ATM, and CHEK2 account for approximately 20% of hereditary breast cancer. This raises the possibility that mutations in other biologically relevant genes may be involved in genetic predisposition to breast cancer. In this study, BRIP1, PALB2, and RAD51C were sequenced for mutations as a result of previously being associated with breast cancer risk due to their role in the double-strand break repair pathway and their close association with BRCA1 and BRCA2. Two truncating mutations in PALB2 (Q66X and W1038X), one of which is has not been reported before, were detected in an independent Australian cohort of 70 individuals with breast or ovarian cancer, and have strong family histories of breast or breast/ovarian cancer. In addition, six missense variants predicted to be causative were detected, one in BRIP1 and five in PALB2. No causative variants were identified in RAD51C. This study supports recent observations that although rare, PALB2 mutations are present in a small but substantial proportion of inherited breast cancer cases, and indicates that RAD51C at a population level does not account for a substantial number of familial breast cancer cases.
Literatur
1.
Lynch HT, Krush AJ (1971) Carcinoma of the breast and ovary in three families. Surg Gynecol Obstet 133(4):644–648PubMed
2.
Lynch HT, Krush AJ, Lemon HM, Kaplan AR, Condit PT, Bottomley RH (1972) Tumor variation in families with breast cancer. JAMA 222(13):1631–1635PubMedCrossRef
3.
Lynch HT, Guirgis HA, Albert S, Brennan M, Lynch J, Kraft C et al (1974) Familial association of carcinoma of the breast and ovary. Surg Gynecol Obstet 138(5):717–724PubMed
4.
5.
National Breast and Ovarian Cancer Centre (2009) Breast cancer risk factors: a review of the evidence. National Breast and Ovarian Cancer Centre, Surry Hills, NSW
6.
7.
Nathanson KL, Wooster R, Weber BL (2001) Breast cancer genetics: what we know and what we need. Nat Med 7(5):552–556PubMedCrossRef
8.
Stratton MR, Rahman N (2008) The emerging landscape of breast cancer susceptibility. Nat Genet 40(1):17–22PubMedCrossRef
9.
Turnbull C, Rahman N (2008) Genetic predisposition to breast cancer: past, present and future. Annu Rev Genom Hum Genet 9:321–345CrossRef
10.
Easton DF, Bishop DT, Ford D, Crockford GP, Consortium BCL (1993) Genetic linkage analysis in familial breast and ovarian cancer. Am J Hum Genet 52(4):678–701PubMed
11.
Couch FJ, DeShano ML, Blackwood MA, Calzone K, Stopfer J, Campeau L et al (1997) BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. NEJM 336(20):1409–1415PubMedCrossRef
12.
Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 62:676–689PubMedCrossRef
13.
Peto J, Collins N, Barfoot R, Seal S, Warren W, Rahman N et al (1999) Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. JNCI 91(11):943–949PubMed
14.
Stoppa-Lyonnet D, Laurent-Puig P, Essioux L, Pages S, Ithier G, Ligot L, Institut Curie Breast Cancer Group et al (1997) BRCA1 sequence variations in 160 individuals referred to a breast/ovarian family cancer clinic. Am J Hum Genet 60(5):1021–1030PubMed
15.
Rosa-Rosa JM, Pita G, Urioste M, Llort G, Brunet J, Lázaro C et al (2009) Genome-wide linkage scan reveals three putative breast-cancer susceptibility loci. Am J Hum Genet 84(2):115–122PubMedCrossRef
16.
Turnbull C, Ahmed S, Morrison J, Pernet D, Renwick A, Maranian M et al. (2010) Genome-wide assocation study identifies five new breast cancer susceptibility loci. Nat Genet. doi:10.​1038/​ng.​586
17.
Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG et al (2007) Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447(7148):1087–1093PubMedCrossRef
18.
Smith P, McGuffog L, Easton DF, Mann GJ, Pupo GM, Newman B et al (2006) A genome wide linkage search for breast cancer susceptibility genes. Genes Chromosomes Cancer 45(7):646–655PubMedCrossRef
19.
Gold B, Kirchhoff T, Stefanov S, Lautenberger J, Viale A, Garber J et al (2008) Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33. Proc Natl Acad Sci USA 105(11):4340–4345PubMedCrossRef
20.
Cox DG, Penney K, Guo Q, Hankinson SE, Hunter DJ (2007) TGFB1 and TGFBR1 polymorphisms and breast cancer risk in the Nurses’ Health Study. BMC Cancer 7(175):175PubMedCrossRef
21.
Meindl A, Hellebrand H, Wiek C, Erven V, Wappenschmidt B, Niederacher D et al (2010) Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet 42(5):410–414PubMedCrossRef
22.
Levy-Lahad E (2010) Fanconi anemia and breast cancer susceptibility meet again. Nat Genet 42(5):368–369PubMedCrossRef
23.
Seal S, Thompson D, Renwick A, Elliott A, Kelly P, Barfoot R et al (2006) Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 38(11):1239–1241PubMedCrossRef
24.
Zhang F, Fan Q, Ren K, Auerbach AD, Andreassen PR (2010) FANCJ/BRIP1 recruitment and regulation of FANCD2 in DNA damage responses. Chromosoma 119(6):637–649PubMedCrossRef
25.
Xia B, Sheng Q, Nakanishi K, Ohashi A, Wu J, Christ N et al (2006) Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell 22(6):719–729PubMedCrossRef
26.
Rahman N, Seal S, Thompson D, Kelly P, Renwick A, Elliott A et al (2007) PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 39(2):165–167PubMedCrossRef
27.
Xia B, Dorsman JC, Ameziane N, de Vries Y, Rooimans MA, Sheng Q et al (2007) Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. Nat Genet 39(2):159–161PubMedCrossRef
28.
Levran O, Attwooll C, Henry RT, Milton KL, Neveling K, Rio P et al (2005) The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia. Nat Genet 37(9):931–933PubMedCrossRef
29.
Vaz F, Hanenberg H, Schuster B, Barker K, Wiek C, Erven V et al (2010) Mutation of the RAD51C gene in a Fanconi anemia-like disorder. Nat Genet 42(5):406–409PubMedCrossRef
30.
Cantor SB, Bell DW, Ganesan S, Kass EM, Drapkin R, Grossman S et al (2001) BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function. Cell 105(1):149–160PubMedCrossRef
31.
Yu X, Chini CC, He M, Mer G, Chen J (2003) The BRCT domain is a phospho-protein binding domain. Science 302(5645):639–642PubMedCrossRef
32.
Cantor S, Drapkin R, Zhang F, Lin Y, Han J, Pamidi S et al (2004) The BRCA1-associated protein BACH1 is a DNA helicase targeted by clinically relevant inactivating mutations. Proc Natl Acad Sci USA 101(8):2357–2362PubMedCrossRef
33.
Sy SM, Huen MS, Chen J (2009) PALB2 is an integral component of the BRCA complex required for homologous recombination repair. Proc Natl Acad Sci USA 106(17):7155–7160PubMedCrossRef
34.
Reid S, Schindler D, Hanenberg H, Barker K, Hanks S, Kalb R et al (2007) Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Genet 39(2):162–164PubMedCrossRef
35.
Scully R, Chen J, Plug A, Xiao Y, Weaver D, Feunteun J et al (1997) Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 88(2):265–275PubMedCrossRef
36.
Venkitaraman AR (2009) Linking the cellular functions of BRCA genes to cancer pathogenesis and treatment. Annu Rev Pathol 4:461–487PubMedCrossRef
37.
Ripperger T, Gadzicki D, Meindl A, Schlegelberger B (2009) Breast cancer susceptibility: current knowledge and implications for genetic counselling. Eur J Hum Genet 17(6):722–731PubMedCrossRef
38.
Tischkowitz M, Xia B, Sabbaghian N, Reis-Filho JS, Hamel N, Li G et al (2007) Analysis of PALB2/FANCN-associated breast cancer families. PNAS 104(16):6788–6793PubMedCrossRef
39.
Rutter JL, Smith AM, Dávila MR, Sigurdson AJ, Ruthann MG, Pineda MA et al (2003) Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals. Hum Mutat 22(2):121–128PubMedCrossRef
40.
Kumar P, Henikoff S, Ng PC (2009) Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 4(7):1073–1081PubMedCrossRef
41.
Ng PC, Henikoff S (2003) SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res 31(13):3812–3814PubMedCrossRef
42.
Bamford S, Dawson E, Forbes S, Clements J, Pettett R, Dogan A et al (2004) The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer 91(2):355–358PubMed
43.
Da Silva L, Lakhani SR (2010) Pathology of hereditary breast cancer. Mod Pathol 23(Suppl 2):S46–S51PubMedCrossRef
44.
Palacios J, Honrado E, Osorio A, Cazorla A, Sarrio D, Barroso A et al (2003) Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers. Clin Cancer Res 9(10 Pt 1):3606–3614PubMed
45.
Tischkowitz M, Xia B (2010) PALB2/FANCN: recombining cancer and Fanconi anemia. Cancer Res 70(19):7353–7359PubMedCrossRef
46.
Foulkes WD, Ghadirian P, Akbari MR, Hamel N, Giroux S, Sabbaghian N et al (2007) Identification of a novel truncating PALB2 mutation and analysis of its contribution to early-onset breast cancer in French–Canadian women. Breast Cancer Res 9(6):83CrossRef
47.
Oliver AW, Swift S, Lord CJ, Ashworth A, Pearl LH (2009) Structural basis for recruitment of BRCA2 by PALB2. EMBO Rep 10(9):990–996PubMedCrossRef
48.
Zhang F, Fan Q, Ren K, Andreassen PR (2009) PALB2 functionally connects the breast cancer susceptibility proteins BRCA1 and BRCA2. Mol Cancer Res 7(7):1110–1118PubMedCrossRef
49.
Zhang F, Ma J, Wu J, Ye L, Cai H, Xia B et al (2009) PALB2 links BRCA1 and BRCA2 in the DNA-damage response. Curr Biol 19(6):524–529PubMedCrossRef
50.
Buisson R, Dion-Cote AM, Coulombe Y, Launay H, Cai H, Stasiak AZ et al (2010) Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination. Nat Struct Mol Biol 17(10):1247–1254PubMedCrossRef
51.
Thompson D, Easton DF (2002) Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94(18):1358–1365PubMed
52.
The Breast Cancer Linkage Consortium (1999) Cancer risks in BRCA2 mutation carriers. JNCI 91(15):1310–1316
Metadaten
Titel
BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer
verfasst von
Michelle W. Wong
Cecilia Nordfors
David Mossman
Gordana Pecenpetelovska
Kelly A. Avery-Kiejda
Bente Talseth-Palmer
Nikola A. Bowden
Rodney J. Scott
Publikationsdatum
01.06.2011
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2011
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-011-1443-0

Weitere Artikel der Ausgabe 3/2011

Breast Cancer Research and Treatment 3/2011 Zur Ausgabe

Preclinical study

Overexpression of the urokinase receptor mRNA splice variant uPAR-del4/5 affects tumor-associated processes of breast cancer cells in vitro and in vivo

Epidemiology

IGFBP1 and IGFBP3 polymorphisms predict circulating IGFBP-3 levels among women from high-risk breast cancer families

Preclinical study

Gene expression analysis reveals a different transcriptomic landscape in female and male breast cancer

Preclinical study

Ionizing radiation or mitomycin-induced micronuclei in lymphocytes of BRCA1 or BRCA2 mutation carriers

Preclinical study

International distribution and age estimation of the Portuguese BRCA2 c.156_157insAlu founder mutation

Epidemiology

Disparities in breast cancer characteristics and outcomes by race/ethnicity

Neu im Fachgebiet Onkologie

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Das sind die führenden Symptome junger Darmkrebspatienten

23.05.2024 Leitsymptome in der Hausarztpraxis Nachrichten

Darmkrebserkrankungen in jüngeren Jahren sind ein zunehmendes Problem, das häufig längere Zeit übersehen wird, gerade weil die Patienten noch nicht alt sind. Welche Anzeichen Ärzte stutzig machen sollten, hat eine Metaanalyse herausgearbeitet.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise